# EDGAR Filing Document

**Accession Number:** 0001651625
**File Stem:** 0000950103-23-003956
**Filing Date:** 2023-3
**Character Count:** 2441
**Document Hash:** 5f13723b2f206704e81e43511cf50c3c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-23-003956.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0000950103-23-003956

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230310

**FILED AS OF DATE**: 20230310

**DATE AS OF CHANGE**: 20230310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AC Immune SA
- **CENTRAL INDEX KEY:** 0001651625
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37891
- **FILM NUMBER:** 23724615

**BUSINESS ADDRESS:**
- **STREET 1:** EPFL INNOVATION PARK, BUILDING B
- **CITY:** 1015 LAUSANNE
- **STATE:** V8
- **ZIP:** 00000
- **BUSINESS PHONE:** 41 21 345 91 21

**MAIL ADDRESS:**
- **STREET 1:** EPFL INNOVATION PARK, BUILDING B
- **CITY:** 1015 LAUSANNE
- **STATE:** V8
- **ZIP:** 00000

UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR<br> 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March, 2023

**Commission file number: 001-37891**

**AC IMMUNE SA**

(Exact Name of Registrant as Specified in Its Charter)

**EPFL Innovation Park<br> Building B<br> 1015 Lausanne, Switzerland**

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

AC Immune is aware that the Federal Deposit Insurance Corp. ("FDIC") has taken control of Silicon Valley Bank ("SVB") due to liquidity concerns. AC Immune holds less than $100,000 on deposit at SVB and otherwise has no exposure to SVB.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| **AC IMMUNE SA** | **AC IMMUNE SA** | **AC IMMUNE SA** |
| By: | /s/ Andrea Pfeifer | /s/ Andrea Pfeifer |
|  | Name: | Andrea Pfeifer |
|  | Title: | Chief Executive Officer |
| By: | /s/ Christopher Roberts | /s/ Christopher Roberts |
|  | Name: | Christopher Roberts |
|  | Title: | Vice President, Finance and Interim Chief Financial Officer |

---

Date: March 10, 2023